Table 4.
Prognostic factors for local tumor recurrence-free survival
| Characteristics | Univariate HR (95% CI) | P-value | Multivariable HR (95% CI) | P-value |
|---|---|---|---|---|
| Age (year) | 0.99 (0.97-1.01) | 0.23 | ||
| Male | 1.05 (0.69-1.60) | 0.83 | ||
| Etiology (HBV vs. other) | 1.26 (0.81-1.98) | 0.31 | ||
| Child-Pugh class B (vs. A) | 1.48 (0.86-2.56) | 0.16 | ||
| AFP (log ng/mL) | 1.05 (0.93-1.17) | 0.44 | ||
| BCLC stage A (vs. 0) | 1.99 (1.27-3.10) | 0.002 | 2.23 (1.40-3.57) | 0.001 |
| Treatment strategy | ||||
| On-demand group | Reference | Reference | ||
| Scheduled second TACE | 0.94 (0.64-1.38) | 0.74 | 0.72 (0.48-1.09) | 0.12 |
HR, harzard ratio; CI, confidence interval; HBV, hepatitis B virus; AFP, alpha fetoprotein; BCLC stage, Barcelona clinic liver cancer stage; TACE, transarterial chemoembolization.